Moreover, in a second work [51], they propose mRNA levels of CD274, CD101, CXCR6, TCRδ, Jα18, and FCεRII as a novel non-invasive biomarker panel for monitoring the EoE disease in patients before and after treatment and to differentiate EoE disease from GERD in patients, emphasizing TCRδ, Jα18, and FCεRII, which seem to be really promising for monitoring and diagnosing EoE. The gene discussed is CD101; the disease is eosinophilic esophagitis.